» Articles » PMID: 26445634

Vitamin D and Bone Minerals Status in the Long-term Survivors of Childhood Acute Lymphoblastic Leukemia

Overview
Journal Int J Prev Med
Date 2015 Oct 8
PMID 26445634
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Low vitamin D and diminished bone minerals with the potential for fractures are one of the nonapparent late effects of acute lymphoblastic leukemia (ALL). Chemotherapy and radiation were known as two important risk factors. We evaluated these late effects in ALL survivors who were treated with chemotherapy or chemo plus cranial radiation therapy.

Methods: In a case-control study, 33 of ALL survivors who were treated with chemotherapy (Group A), and 33 subjects who were treated with chemoplus cranial radiation (Group B) were compared against 33 matched age, sex, and pubertal stage of their healthy siblings (Group C). Standard anthropometric data were collected as well as Tanner staging for puberty, number of fractures since treatment, serum calcium (Ca), phosphorus (P), magnesium (Mg), alkaline phosphatase, parathyroid hormone, and 25-hydroxyvitamin D (25(OH) D). The independent t-test, one-way ANOVA, Chi-square test, and Tukey's test were used to analyze the data.

Results: The findings indicated that the mean serum levels of 25(OH) D in ALL survivors (i.e. Groups A and B) with age mean score of 11.2 years and 12.3 years, average treatment length: 3.25 years and average time after treatment completion: 4 years, was lower compared to the controls group (12.94 ± 6.69, 14.6 ± 8.1, 20.16 ± 10.83, respectively, P < 0.001) but no significant difference was observed between Group A and B in this regard (P > 0.05). Other clinical and laboratory parameters had no significant differences between the survivors and control. Vitamin D deficiency (<20 ng/ml) was observed in 27% of group A and 24% of group B and vitamin D insufficiency (20-30 ng/ml) in 72.7% and 69.6% survivors of Group A and B and 48.5% of controls group (P = 0.003).

Conclusions: ALL treatment is associated with the increase in prevalence of vitamin D insufficiency in the childhood ALL survivors and since the low vitamin D level potentially increases the risk of low bone density, subsequent malignancies, and cardiovascular disease in the survivors, close follow-up of such patients are highly recommended to prevent the stated complications.

Citing Articles

Metabolic/endocrine disorders in survivors of childhood-onset and cranial radiotherapy- treated ALL/NHL: a meta-analysis.

Zhang D, Gu M Reprod Biol Endocrinol. 2023; 21(1):91.

PMID: 37794442 PMC: 10548660. DOI: 10.1186/s12958-023-01137-y.


Vitamin D abnormalities of children with recurrence of malignancy and comparison with newly diagnosed patients.

Reisi N, Mirzaei A, Moafi A, Raeissi P, Naghdhassani M Caspian J Intern Med. 2022; 13(4):735-740.

PMID: 36420327 PMC: 9659826. DOI: 10.22088/cjim.13.4.735.


Evaluating the Effect of Induction Chemotherapy on Bone Metabolizing Nutrients in Patients of Acute Lymphoblastic Leukemia.

Khan A, Zeb J, Farooq N, Farid N, Zeb R, Shoaib M Cureus. 2022; 14(5):e25403.

PMID: 35774667 PMC: 9239291. DOI: 10.7759/cureus.25403.


Changes in Metabolic Parameters in Patients with Diabetic Kidney Disease Depending on the Status of D3.

Pastukhova Y, Luzza F, Shevel S, Savchuk O, Ostapchenko L, Falalyeyeva T Rev Recent Clin Trials. 2022; 17(4):280-290.

PMID: 35319388 DOI: 10.2174/1574887117666220321152855.


Genetic polymorphism of vitamin D receptors and plasminogen activator inhibitor-1 and osteonecrosis risk in childhood acute lymphoblastic leukemia.

Sherief L, Beshir M, Raafat N, Abdelkhalek E, Mokhtar W, Elgerby K Mol Genet Genomic Med. 2021; 9(7):e1700.

PMID: 34042331 PMC: 8372120. DOI: 10.1002/mgg3.1700.


References
1.
Kaste S, Rose S, Boyett J, Lustig R, Rivera G, Pui C . Bone mineral decrements in survivors of childhood acute lymphoblastic leukemia: frequency of occurrence and risk factors for their development. Leukemia. 2001; 15(5):728-34. DOI: 10.1038/sj.leu.2402078. View

2.
Simmons J, Chow E, Koehler E, Esbenshade A, Smith L, Sanders J . Significant 25-hydroxyvitamin D deficiency in child and adolescent survivors of acute lymphoblastic leukemia: treatment with chemotherapy compared with allogeneic stem cell transplant. Pediatr Blood Cancer. 2011; 56(7):1114-9. PMC: 3135735. DOI: 10.1002/pbc.22949. View

3.
Lee H, Muindi J, Tan W, Hu Q, Wang D, Liu S . Low 25(OH) vitamin D3 levels are associated with adverse outcome in newly diagnosed, intensively treated adult acute myeloid leukemia. Cancer. 2013; 120(4):521-9. PMC: 3948325. DOI: 10.1002/cncr.28368. View

4.
Arikoski P, Komulainen J, Riikonen P, Jurvelin J, Voutilainen R, Kroger H . Reduced bone density at completion of chemotherapy for a malignancy. Arch Dis Child. 1999; 80(2):143-8. PMC: 1717834. DOI: 10.1136/adc.80.2.143. View

5.
How K, Hazewinkel H, Mol J . Dietary vitamin D dependence of cat and dog due to inadequate cutaneous synthesis of vitamin D. Gen Comp Endocrinol. 1994; 96(1):12-8. DOI: 10.1006/gcen.1994.1154. View